arXiv AI

Treatment Response Optimized Clinical Decision Support AI System via Digital Twin Simulation

arXiv:2606. 17405v1 Announce Type: new Abstract: Clinical decision support AI systems (CDSASs) must adapt to evolving patient conditions in real-time while adhering to strict safety constraints.

arXiv AI
Sep 2

Towards AI-Assisted Clinical Trial Matching: Practical Considerations, Multicenter Evaluation, and Real-World Deployment

arXiv:2609.01202v1 Announce Type: cross Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...

By Yin Fang, Qiao Jin, Shubo Tian, Lauren He, Maya Geer, Noor Naffakh, Ryan Huu-Tuan Nguyen, Zifeng Wang, Jimeng Sun, Charalampos S. Floudas, James L. Gulley, Kamilia Moalem, Catarina Martins Maia, Amanda Nottke, Juan W. Valle, Melinda Bachini, Lourdes Rocha-Nussbaum, Kari Ramage, Nikita Curry, Megan Barnes, Mandy Mansaray, Darlene Gabeau, Craig E. Grossman, Heath Skinner, Michael Burczynski, NIH-TrialBench Consortium, Zhiyong Lu
arXiv Machine Learning
Jun 2

MedGym:A Unified Continuous-Time Benchmark for Dynamic Medical Treatment Reinforcement Learning

arXiv:2606. 01028v1 Announce Type: new Abstract: Medical treatment recommendation poses several challenges to reinforcement learning (RL): patient physiology evolves in continuous time, measurements and interventions are performed at irregular intervals, and treatment effects vary substantially across individuals.

By Yuepeng Wang, Ken Kawano, Yongqi Zhou, Yoshihiko Fujisawa, Richard Weiss, Akifumi Wachi, Katsuki Fujisawa, Ying Chen, Mehrshad Sadria, Xin Liu, Kyoung-Sook Kim, Xiao Hu, Sebastien Gros, Xun Shen
arXiv AI
Sep 15

Causal multi-modal AI for personalized chemosensitivity prediction

A causal multi-modal AI model was developed to predict personalized chemosensitivity in breast cancer patients using routine pathology and clinical data. Trained on 9,141 patients from nine countries and validated on 1,994 patients from three countries, the model produced treatment-specific recurrence probabilities with near-perfect calibration and strong prognostic discrimination over 5- and 10-year horizons. It outperformed existing recurrence-score tests and could reduce chemotherapy prescriptions by 30% while maintaining recurrence-free rates, with predictive performance also transferring to non-breast cancers.

By Dhruva Biswas, Jeroen Berrevoets, Alec McClean, Linus Bao, Jungkyu Park, Ken G. Zeng, Joseph Cappadona, Cerise Tang, Chuwen Liu, Bartosz Machura, Yin Wu, Valerie Speirs, Hatem Soliman, Rohit Bhargava, Sheheryar Kabraji, Thaer Khoury, David Page, Brian Piening, Carlo Bifulco, Claudia Meurs, Pieter Westenend, Sylvie Chabaud, Jerome Lemonnier, Paul H. Cottu, Florence Dalenc, Fabrice Andre, Frederique Madeleine Penault-Llorca, Thomas Bachelot, Frederick Howard, Francisco J. Esteva, Kevin Kalinsky, Lajos Pusztai, Jan Witowski, Krzysztof J. Geras
arXiv Machine Learning
Sep 22

A Unified Benchmark for Dynamic Medical Treatment Reinforcement Learning

The paper introduces MedGym, a benchmark environment for dynamic medical treatment recommendation that models patient evolution in continuous time using Physics-Informed Neural Networks. It addresses gaps in existing reinforcement learning (RL) approaches by allowing evaluation of RL methods under irregular measurement intervals, personalized treatment responses, and safety considerations. MedGym enables direct comparison between discrete-time and continuous-time RL methods and supports clinically relevant metrics such as personalization and trajectory-level safety.

By Yuepeng Wang, Ken Kawano, Yoshihiko Fujisawa, Yongqi Zhou, Akifumi Wachi, Mehrshad Sadria, Lei Zhou, Richard Weiss, Katsuki Fujisawa, Ying Chen, Xin Liu, Kyoung-Sook Kim, Xiao Hu, Sebastien Gros, Xun Shen
arXiv Machine Learning
Jul 21

Enhancing Personalized Bladder Cancer Treatment Through Reinforcement Learning: A Recurrent Patient State Transition Decision Support Framework

arXiv:2607. 16916v1 Announce Type: new Abstract: Bladder cancer treatment requires personalized and adaptive decision-making, particularly for recurrent disease, where treatment effectiveness changes across successive clinical episodes.

By Divyansh Chawla, Anshu Garg, Isshaan Singh